Phase 3 Non-Alcoholic Fatty Liver Disease Trial, RecruitingNCT07165028Sponsor: Eli Lilly and CompanyCondition: Non-Alcoholic Fatty Liver Disease
Printed from Voxsanity (voxsanity.com.au) — NCT07165028 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
Your liver contains a certain level of fat (at least 8%), which would be measured before joining (confirm with trial site)
A specific liver health score called an ELF score falls within a certain range, suggesting a moderate level of liver scarring or damage (confirm with trial site)
A scan measuring the stiffness of your liver shows results within a specific range, suggesting a certain level of liver scarring (confirm with trial site)
Who may not be able to join:
You have a liver disease other than a condition called MASLD (a type of fatty liver disease related to metabolism)
Your body weight is considered lower than a certain threshold relative to your height (a BMI under 25)
You have had serious liver complications in the past, such as swollen veins in the throat or stomach, fluid build-up in the belly, or episodes of confusion caused by liver problems
You have lost more than 11 pounds in the 3 months before joining the trial
A blood test shows your average blood sugar levels over the past few months are above a certain high level (HbA1c greater than 10%)
You have Type 1 diabetes
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Royal Brisbane and Women's Hospital, Brisbane,
+61 7 36468111
Core Research Group, Brisbane,
61738765688
Mater Misericordiae Limited, Brisbane,
Gallipoli Medical Research Ltd, Brisbane,
0733947284
Genesis Research Services, Broadmeadow,
Austin Health, Heidelberg,
61 3 9496 2787
Ipswich Hospital, Ipswich,
0402112100
Fiona Stanley Hospital, Murdoch,
TrialsWest - Osborne Park, Osborne Park,
The Royal Melbourne Hospital, Parkville,
Gold Coast University Hospital, Southport,
Westmead Hospital, Westmead,
0288907705
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT07165028
Sponsor: Eli Lilly and Company
Phase: Phase 3
Status: Recruiting
Condition: Non-Alcoholic Fatty Liver Disease
Trial contact: 1-317-615-4559
More information: https://clinicaltrials.gov/study/NCT07165028
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
Your liver contains a certain level of fat (at least 8%), which would be measured before joining (confirm with trial site)
A specific liver health score called an ELF score falls within a certain range, suggesting a moderate level of liver scarring or damage (confirm with trial site)
A scan measuring the stiffness of your liver shows results within a specific range, suggesting a certain level of liver scarring (confirm with trial site)
Who may not be able to join:
You have a liver disease other than a condition called MASLD (a type of fatty liver disease related to metabolism)
Your body weight is considered lower than a certain threshold relative to your height (a BMI under 25)
You have had serious liver complications in the past, such as swollen veins in the throat or stomach, fluid build-up in the belly, or episodes of confusion caused by liver problems
You have lost more than 11 pounds in the 3 months before joining the trial
A blood test shows your average blood sugar levels over the past few months are above a certain high level (HbA1c greater than 10%)
You have Type 1 diabetes
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
🇦🇷 Argentina
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇷 Brazil
🇧🇬 Bulgaria
🇨🇦 Canada
🇨🇳 China
🇨🇿 Czechia
🇫🇷 France
🇩🇪 Germany
Hong Kong
🇭🇺 Hungary
🇮🇳 India
🇮🇱 Israel
🇮🇹 Italy
🇯🇵 Japan
🇲🇽 Mexico
🇳🇱 Netherlands
🇳🇿 New Zealand
🇳🇴 Norway
🇵🇱 Poland
🇵🇹 Portugal
Puerto Rico
🇷🇴 Romania
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇨🇭 Switzerland
🇹🇼 Taiwan
Turkey (Türkiye)
🇺🇦 Ukraine
🇬🇧 United Kingdom
🇺🇸 United States
15 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Time to First Occurrence of Any Component of the Composite Endpoint for Major Adverse Liver Outcomes (MALO)
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.